NeuroVive Pharmaceutical AB Book/Share
What is the Book/Share of NeuroVive Pharmaceutical AB?
The Book/Share of NeuroVive Pharmaceutical AB is 0.06
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Miscellaneous sector on LSE compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with book/share similar to NeuroVive Pharmaceutical AB
- Consolidated Tin Mines has Book/Share of 0.06
- Drummond Ventures has Book/Share of 0.06
- J4 Ventures has Book/Share of 0.06
- East West Petroleum has Book/Share of 0.06
- Polyard Petroleum International has Book/Share of 0.06
- El Nino Ventures has Book/Share of 0.06
- NeuroVive Pharmaceutical AB has Book/Share of 0.06
- Liberty Gold has Book/Share of 0.06
- China Smartpay has Book/Share of 0.06
- Battery Road Capital has Book/Share of 0.06
- Conroy Gold and Natural Resources plc has Book/Share of 0.06
- Keybridge Capital has Book/Share of 0.06
- Blockmint Technologies has Book/Share of 0.06